Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Melese Alemnew Ayal & Alemseged Beyene Berha. (2023) Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study. HIV/AIDS - Research and Palliative Care 15, pages 173-190.
Read now
Read now
Fabrice Bailly & Philippe Cotelle. (2015) The preclinical discovery and development of dolutegravir for the treatment of HIV. Expert Opinion on Drug Discovery 10:11, pages 1243-1253.
Read now
Read now
Articles from other publishers (10)
Mathew K. Koech, Shamim M. Ali, Mercy J. Karoney & Gabriel Kigen. (2022) Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report. Journal of Medical Case Reports 16:1.
Crossref
Crossref
Chenglin Hong, Nancy Puttkammer, Serhii Riabokon, Myroslava Germanovich, Alyona Shost, Canada Parrish, Anna Shapoval & Kostyantyn Dumchev. (2021) Patient-Reported Treatment Satisfaction and Quality of Life Among People Living with HIV Following the Introduction of Dolutegravir-Based ART Regimens in Ukraine. AIDS and Behavior 26:4, pages 1056-1073.
Crossref
Crossref
Ahmed Serag, Mohamed A. Hasan, Enas H. Tolba, Ahmed M. Abdelzaher & Ayman Abo Elmaaty. (2022) Analysis of the ternary antiretroviral therapy dolutegravir, lamivudine and abacavir using UV spectrophotometry and chemometric tools. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 264, pages 120334.
Crossref
Crossref
Malewe Kolou, Armel Poda, Zelica Diallo, Esther Konou, Tatiana Dokpomiwa, Jacques Zoungrana, Mounerou Salou, Lionèle Mba-Tchounga, André Bigot, Abdoul-Salam Ouedraogo, Marielle Bouyout-Akoutet, Didier K. Ekouevi & Serge P. Eholie. (2021) Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa. BMC Immunology 22:1.
Crossref
Crossref
Mario Cruciani & Saverio G. Parisi. (2019) Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis. PLOS ONE 14:9, pages e0222229.
Crossref
Crossref
Ying-Shan Han, Thibault Mesplède & Mark A. Wainberg. 2017. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
559
564
.
Muriel Billamboz, Virginie Suchaud, Fabrice Bailly, Cedric Lion, Marie-Line Andréola, Frauke Christ, Zeger Debyser & Philippe Cotelle. (2016) 2-hydroxyisoquinoline-1,3(2 H ,4 H )-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4. European Journal of Medicinal Chemistry 117, pages 256-268.
Crossref
Crossref
Mark A. WainbergYing-Shan HanThibault Mesplède. (2016) Might dolutegravir be part of a functional cure for HIV?. Canadian Journal of Microbiology 62:5, pages 375-382.
Crossref
Crossref
Massimiliano Lanzafame, Davide Gibellini, Emanuela Lattuada, Caterina Signoretto, Romualdo Mazzi, Ercole Concia & Sandro Vento. (2016) Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load. JAIDS Journal of Acquired Immune Deficiency Syndromes 72:1, pages e12-e14.
Crossref
Crossref
Gregory Hook, J. Steven Jacobsen, Kenneth Grabstein, Mark Kindy & Vivian Hook. (2015) Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate. Frontiers in Neurology 6.
Crossref
Crossref